Juanito Uy, MD
Endocrinology, Diabetes & Metabolism · Muncie, INNPI 1851531149
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by AstraZeneca at 46.6% of the total. Reporting peaked in 2019 at $12,977 and has fallen 91.4% since, to $1,110 in 2025.
Across 831 payments — averaging $38.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Merck$7K
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Abbott$1K
- Amgen$784
- plus $5K from 36 others
What the payments were for
- Speaking & faculty fees$17,91057%
- Travel & lodging$2761%
- Food & beverage$13,23142%
- Education$2161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$13,069
- STEGLATRO$5,573
- Ozempic$232
- SYMBICORT$224
- DEXCOM G7 GSS (161)$161
- DEXCOM STELO GLUCOSE BIOSENSOR$161
- FreeStyle Lite system$150
- AIRSUPRA$145
- Yorvipath$125
- EVENITY$125
- ZEPBOUND$125
- TEPEZZA$125
- Wegovy$123
- LOKELMA$117
- FreeStyle Libre Pro$116
- BREZTRI AEROSPHERE$106
How this compares
$31,633 in reported general payments places this provider in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 364 | $481,225 |
| OzempicSemaglutide | 213 | $297,611 |
| FarxigaDapagliflozin Propanediol | 174 | $183,974 |
| TrulicityDulaglutide | 106 | $152,457 |
| JardianceEmpagliflozin | 92 | $117,795 |
| Tresiba Flextouch U-100Insulin Degludec | 158 | $97,004 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 82 | $92,917 |
| Xigduo XrDapaglifloz Propaned/Metformin | 74 | $88,174 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 67 | $77,452 |
| Gvoke Hypopen 2-PackGlucagon | 96 | $64,412 |
| JanuviaSitagliptin Phosphate | 45 | $54,134 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $49,969 |
| Humalog Kwikpen U-100Insulin Lispro | 135 | $49,299 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $47,161 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $45,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $1,721 | $682,930552 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,224 | $334,371262 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $534 | $231,591197 claims |
| AstraZenecaFarxiga | $14,748 | $183,974174 claims |
| MerckJanuvia, Janumet Xr | $6,689 | $79,76674 claims |
| AbbVieSynthroid | $409 | $39,200384 claims |
| Amneal Pharmaceuticals LLCUnithroid | $188 | $33,435556 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Muncie
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.